Literature DB >> 30177223

Computerized registry of patients with hemorrhagic hereditary telangiectasia (RiHHTa Registry) in Spain: Objectives, methods, and preliminary results.

A Riera-Mestre1, J M Mora Luján2, R Sanchez Martínez3, M A Torralba Cabeza4, J L Patier de la Peña5, M C Juyol Rodrigo6, D Lopez Wolf7, A Ojeda Sosa8, L Monserrat9, M López Rodríguez10.   

Abstract

INTRODUCTION: Hereditary hemorrhagic telangiectasia (HHT) is a rare disease with autosomal dominant inheritance that causes systemic vascular affectation. MATERIAL AND
METHOD: After development a multicentric Spanish national registry, called RiHHTa, main clinical manifestations and diagnostic procedures of the first patients introduced are described.
RESULTS: 141 patients were included, of which 91 (64.5%) were women. The mean age at diagnosis was 42 years. Mutations in the ACVRL1 gene predominated over the ENG gene. The initial symptom was recurrent epistaxis in 130 (92.2%) patients and in three (2.1%), brain abscess. Pulmonary arteriovenous (AV) fistula were detected in 36 (45%) of the 79 patients who underwent thoracic CT angiography. The contrast echocardiography detected very few bubbles (grade I) or none, in 36 (45%) of these 79 affected patients. In 43 (67.2%) of the 64 patients with an abdominal CT angiography, hepatic vascular malformations were detected, mostly telangiectasias, AV and arterio-portal fistula, and extrahepatic in 14 (10%) subjects. More than half of the patients were screened for the presence of brain arteriovenous malformations which was found in 3.9% of them. The upper part of the intestinal tube was the most (95%) affected region.
CONCLUSION: The RiHHTa Registry allows improving the management of patients with HHT. An inadequate use of thoracic CT angiography and the usefulness of abdominal CT angiography has been detected in order to define subtypes of hepatic vascular involvement and detect extrahepatic vascular involvement.
Copyright © 2018 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved.

Entities:  

Keywords:  Enfermedades minoritarias; Hemorrhagic hereditary telangiectasia; Rare diseases; Registro RiHHTa; RiHHTa Registry; Telangiectasia hemorrágica hereditaria

Year:  2018        PMID: 30177223     DOI: 10.1016/j.rce.2018.07.002

Source DB:  PubMed          Journal:  Rev Clin Esp (Barc)        ISSN: 2254-8874


  5 in total

1.  Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry.

Authors:  Antoni Riera-Mestre; José María Mora-Luján; Javier Trujillo-Santos; Jorge Del Toro; José Antonio Nieto; José María Pedrajas; Raquel López-Reyes; Silvia Soler; Aitor Ballaz; Pau Cerdà; Manel Monreal
Journal:  Orphanet J Rare Dis       Date:  2019-08-09       Impact factor: 4.123

2.  PI3K (Phosphatidylinositol 3-Kinase) Activation and Endothelial Cell Proliferation in Patients with Hemorrhagic Hereditary Telangiectasia Type 1.

Authors:  Adriana Iriarte; Agnes Figueras; Pau Cerdà; José María Mora; Anna Jucglà; Rosa Penín; Francesc Viñals; Antoni Riera-Mestre
Journal:  Cells       Date:  2019-08-24       Impact factor: 6.600

3.  Current HHT genetic overview in Spain and its phenotypic correlation: data from RiHHTa registry.

Authors:  Rosario Sánchez-Martínez; Adriana Iriarte; José María Mora-Luján; José Luis Patier; Daniel López-Wolf; Ana Ojeda; Miguel Angel Torralba; María Coloma Juyol; Ricardo Gil; Sol Añón; Joel Salazar-Mendiguchía; Antoni Riera-Mestre
Journal:  Orphanet J Rare Dis       Date:  2020-06-05       Impact factor: 4.123

4.  Gender differences in hereditary hemorrhagic telangiectasia severity.

Authors:  J M Mora-Luján; A Iriarte; E Alba; M A Sánchez-Corral; P Cerdà; F Cruellas; Q Ordi; X Corbella; J Ribas; J Castellote; A Riera-Mestre
Journal:  Orphanet J Rare Dis       Date:  2020-03-02       Impact factor: 4.123

5.  Gastrointestinal Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia: Risk Factors and Endoscopic Findings.

Authors:  José María Mora-Luján; Adriana Iriarte; Esther Alba; Miguel Ángel Sánchez-Corral; Ana Berrozpe; Pau Cerdà; Francesc Cruellas; Jesús Ribas; Jose Castellote; Antoni Riera-Mestre
Journal:  J Clin Med       Date:  2019-12-28       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.